PEAK6’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$36.8M Buy
970,600
+863,400
+805% +$39.8M 0.07% 195
2026
Q2
$5.14M Sell
107,200
-536,500
-83% -$23.1M 0.01% 840
2026
Q1
$23.7M Sell
643,700
-773,300
-55% -$36.6M 0.06% 304
2025
Q4
$72.1M Buy
1,417,000
+139,400
+11% +$7.13M 0.13% 131
2025
Q3
$70.9M Buy
1,277,600
+1,000,400
+361% +$58.6M 0.1% 147
2025
Q2
$19.1M Sell
277,200
-304,400
-52% -$20.7M 0.04% 397
2025
Q1
$40.4M Buy
581,600
+182,500
+46% +$15.1M 0.09% 184
2024
Q4
$34.3M Buy
+399,100
New +$43.2M 0.07% 227

Other funds holding NVO

PEAK6's NVO Position: Q3 2026 in Review

PEAK6 opened a new position in Novo Nordisk (NVO) in Q3 2026: 58,026 shares worth $2.2M. The stake represents ﹤0.01% of the portfolio and ranks #1207 among its holdings. This is a return to the name: PEAK6 previously reported a position in NVO as recently as Q1 2026.

PEAK6 first reported a position in NVO in Q4 2024 and has held it in 7 quarters since. The position peaked at $17.8M in Q1 2025. 1,232 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • PEAK6 held 58,026 shares of Novo Nordisk worth $2.2M as of Q3 2026.
  • Novo Nordisk was a new PEAK6 position in Q3 2026.
  • Novo Nordisk made up ﹤0.01% of PEAK6's portfolio in Q3 2026, its #1207 holding.
  • PEAK6 first reported a position in Novo Nordisk in Q4 2024 and has held it in 7 quarters since.
  • PEAK6's Novo Nordisk position peaked at $17.8M in Q1 2025.
  • 1,232 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on PEAK6's 13F filing for Q3 2026, filed 13 Nov 2026.